# Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

> **NCT02844439** · PHASE2 · COMPLETED · sponsor: **Kadmon Corporation, LLC** · enrollment: 40 (actual)

## Conditions studied

- Glioblastoma
- Recurrent Glioblastoma
- Brain Tumor

## Interventions

- **DRUG:** Tesevatinib

## Key facts

- **NCT ID:** NCT02844439
- **Lead sponsor:** Kadmon Corporation, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2020-04-30
- **Final completion:** 2020-04-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02844439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02844439, "Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT02844439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*